Department of Neuroscience, Ophthalmology and Genetics, University of Genova, Via De Toni 5, 16132 Genova, Italy.
Neuroscience. 2011 Dec 29;199:386-93. doi: 10.1016/j.neuroscience.2011.09.018. Epub 2011 Sep 19.
Creatine, an ergogenic compound essential for brain function, is very hydrophilic and needs a transporter to cross lipid-rich cells' plasma membranes. Hereditary creatine transporter deficiency is a severe incurable neurological disease where creatine is missing from the brain. Creatine esters are more lipophylic than creatine and may not need the transporter to cross plasma membranes. Thus, they may represent a useful therapy for hereditary creatine transporter deficiency. Creatine ethyl ester (CEE) is commercially available and widely used as a nutritional supplement. It was reported that it enters the cells of patients lacking the transporter but was not useful when administered in vivo, by oral route, to affected patients. In this paper we investigated the effects of CEE in in vitro brain slices before and after biochemical block of the creatine transporter. We found that CEE is rapidly degraded in the aqueous incubation medium to creatinine, however it remains in solution long enough to cause an increase in tissue content of creatine and, more prominently, phosphocreatine. Both CEE and creatine delayed the anoxia-induced failure of synaptic transmission, and there was no difference between the two compounds. Contrary to what we expected, CEE did not increase tissue creatine content after the creatine transporter was blocked. We confirm that CEE is probably not an effective treatment for hereditary creatine transporter deficiency. Two factors seem to affect the possibility for creatine esters to be exploited in the therapy of creatine transporter deficiency. First, the size of their alcohol moiety should be increased since this would increase the lipophilicity of the compound and improve its ability to diffuse through biological membranes. Second, creatine esters should be further modified to slow their degradation to creatinine and increase their half-life in aqueous solutions. Moreover, we should not forget the possibility that they are degraded in vivo by plasma esterases.
肌酸是一种必需的脑功能增效化合物,具有很强的亲水性,需要载体才能穿过富含脂质的细胞质膜。遗传性肌酸转运蛋白缺乏症是一种严重的、无法治愈的神经疾病,大脑中缺乏肌酸。肌酸酯比肌酸更亲脂,可能不需要载体就能穿过质膜。因此,它们可能是遗传性肌酸转运蛋白缺乏症的一种有用治疗方法。肌酸乙酯(CEE)是一种商业上可获得的、广泛用作营养补充剂的物质。据报道,它可以进入缺乏转运体的患者细胞,但当通过口服途径给予受影响的患者时,在体内并不有用。在本文中,我们研究了 CEE 在生化阻断肌酸转运体前后对体外脑片的影响。我们发现 CEE 在水性孵育介质中迅速降解为肌酸酐,但它在溶液中停留的时间足以导致组织中肌酸含量增加,更明显的是磷酸肌酸含量增加。CEE 和肌酸都延迟了缺氧引起的突触传递失败,两种化合物之间没有差异。与我们的预期相反,在阻断肌酸转运体后,CEE 并没有增加组织中的肌酸含量。我们证实 CEE 可能不是遗传性肌酸转运蛋白缺乏症的有效治疗方法。有两个因素似乎会影响肌酸酯在肌酸转运蛋白缺乏症治疗中的应用可能性。首先,应该增加其醇部分的大小,因为这会增加化合物的亲脂性,并提高其穿过生物膜的能力。其次,应该进一步修饰肌酸酯以减慢其降解为肌酸的速度,并增加其在水溶液中的半衰期。此外,我们不应忘记它们在体内可能被血浆酯酶降解的可能性。